Q-omics provides the consensus-scored CCDC30 profile across patient tissues and cancer cell-line models. CCDC30 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC30 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CCDC30 RNA expression shows 21,225 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where CCDC30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC30 survival associations across molecular data types. CCDC30 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC30 RNA expression–survival associations across cancer types. High CCDC30 expression shows unfavorable associations in LGG, KICH and LUSC, but favorable associations in HNSC, KIRP and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC30 RNA expression.
This table summarizes CCDC30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC30 shows lower tumor expression in KICH, THCA, LUSC, LUAD and KIRC and higher tumor expression in BRCA. The KICH box plot shows higher CCDC30 RNA expression in normal versus tumor tissue (log2 FC = −1.582, t-test p < 0.001).
This table shows molecular features associated with CCDC30 in patient tissues and cancer cell lines. In patient samples, CCDC30 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
